KRAS Testing: A Tool for the Implementation of Personalized Medicine

Area of Science:

• Oncology
• Molecular Diagnostics
• Genetics

Background:

• Activating mutations in KRAS codons 12, 13, and 61 are prevalent in several cancers.
• These KRAS mutations confer resistance to anti-EGFR therapies, impacting treatment efficacy.

Purpose of the Study:

• To review and summarize KRAS mutation testing methods used in clinical practice.
• To guide the selection and preparation of samples for accurate KRAS testing.

Main Methods:

• Literature review of KRAS mutation testing methodologies.
• Analysis of test performance, cost, turnaround times, and detection limits.

Main Results:

• Multiple methods exist for clinical KRAS mutation testing, each with varying performance characteristics.
• Sample selection and preparation are critical for reliable test results.

Conclusions:

• KRAS mutation testing is essential for personalized anti-EGFR therapy selection.
• Understanding different testing methodologies and sample requirements optimizes clinical decision-making.